Tirzepatide + Semaglutide

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Type 2 Diabetes

Conditions

Type 2 Diabetes

Trial Timeline

Jul 30, 2019 โ†’ Feb 15, 2021

About Tirzepatide + Semaglutide

Tirzepatide + Semaglutide is a phase 3 stage product being developed by Eli Lilly for Type 2 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT03987919. Target conditions include Type 2 Diabetes.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT06354101Pre-clinicalWithdrawn
NCT05822830Phase 3Completed
NCT03987919Phase 3Completed